Resistance of Transgenic Mice Expressing Human Group II Phospholipase A2 to Escherichia coli Infection

AUTOR(ES)

Laine, V. Jukka O.

FONTE

American Society for Microbiology

RESUMO

Group II phospholipase A2 (PLA2) is a newly recognized antibacterial acute-phase protein. Recently we observed that transgenic mice expressing group II PLA2 (PLA2+ mice) were able to resist experimental Staphylococcus aureus infection by killing the bacteria, as indicated by improved survival and by the small numbers of live bacteria in their tissues (V. J. O. Laine, D. S. Grass, and T. J. Nevalainen, J. Immunol. 162:7402–7408, 1999). To establish the role of group II PLA2 in Escherichia coli infection, the host responses of PLA2+ mice and their PLA2-deficient C57BL/6J littermates (PLA2− mice) were studied after intraperitoneal administration of E. coli. The levels of group II PLA2 in sera of PLA2+ mice increased after the administration of E. coli, and the concentration of group II PLA2 correlated significantly with the catalytic activity of PLA2 in serum. PLA2+ mice showed lower rates of mortality and less bacterial growth in peritoneal lavage fluid, blood, and spleen and liver tissues than PLA2− mice. Unlike the observations with staphylococcal infection, serum and peritoneal lavage fluid did not inhibit the growth of E. coli in vitro. The results indicate that expression of the group II PLA2 transgene improves the host defense of mice against E. coli infection.

Documentos Relacionados

• Determinants of activation by complement of group II phospholipase A2 acting against Escherichia coli.
• Gene expression of group II phospholipase A2 in intestine in ulcerative colitis.
• Induction of circulating group II phospholipase A2 expression in adults with malaria.
• Enhanced virus resistance of transgenic mice expressing the human MxA protein.
• Total chemical synthesis of enzymatically active human type II secretory phospholipase A2